Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile

Significant improvements observed in secondary endpoints, including reductions in liver fat, inflammation and biomarkers of fibrosis

Read more at globenewswire.com